Sugi Predict

Sugi Predict / Compounds / SCHEMBL191130

SCHEMBL191130

SCHEMBL191130

CC(C)N(C[C@@H](C(=O)O)c1ccc(Cl)cc1)C(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.45
▸ CYP2C9 P11712 3/20 0.40
▸ CYP2C19 P33261 3/20 0.40
▸ KMT2A Q03164 2/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ ITGB1 P05556 1/20 0.37
▸ ITGA4 P13612 1/20 0.37
▸ MT-CO2 P00403 1/20 0.36
▸ CYP2D6 P10635 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ NFKB1 P19838 1/20 0.36
▸ PPARG P37231 1/20 0.35
▸ PPARA Q07869 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ PMP22 Q01453 1/20 0.35
▸ NLRP3 Q96P20 1/20 0.35
▸ AHCY P23526 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL191131 1.00 POLB (0.45) POLBCYP2C9CYP2C19KMT2AL3MBTL1
SCHEMBL16719281 1.00 POLB (0.45) POLBCYP2C9CYP2C19KMT2AL3MBTL1
SCHEMBL30571417 1.00 POLB (0.45) POLBCYP2C9CYP2C19KMT2AL3MBTL1
SCHEMBL16719301 0.99 POLB (0.44) POLBCYP2C9CYP2C19KMT2AL3MBTL1
SCHEMBL16719299 0.99 POLB (0.44) POLBCYP2C9CYP2C19KMT2AL3MBTL1
SCHEMBL191358 0.88 L3MBTL1 (0.49) POLBCYP2C9CYP2C19L3MBTL1MT-CO2
SCHEMBL16719300 0.88 L3MBTL1 (0.36) POLBCYP2C9CYP2C19L3MBTL1MT-CO2
SCHEMBL21485111 0.88 L3MBTL1 (0.36) POLBCYP2C9CYP2C19L3MBTL1MT-CO2
Potassium Ion SCHEMBL191177 0.88 L3MBTL1 (0.36) POLBCYP2C9CYP2C19L3MBTL1MT-CO2
SCHEMBL2573285 0.87 PTGS1 (0.36) L3MBTL1ITGB1ITGA4ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119330859-A Preparation method of (S) -3- [ tert-butoxycarbonyl (isopropyl) amino ] -2- (4-chlorophenyl) propionic acid 上海农林职业技术学院 2025-01-21 — — CN claimed
EP-3068770-B1 PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS HOFFMANN LA ROCHE (CH) 2019-10-23 — — EP claimed
US-10435378-B2 Processes for the preparation of pyrimidinylcyclopentane compounds GENENTECH, INC. (US) 2019-10-08 — — US claimed
US-20180086722-A1 PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS GENENTECH, INC. (US) 2018-03-29 — — US claimed
US-20160297773-A1 PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS GENENTECH, INC. (US) 2016-10-13 — — US claimed
EP-3068770-A1 PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS F. Hoffmann-La Roche AG (CH) 2016-09-21 — — EP claimed
WO-2015073739-A1 PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2015-05-21 — — WO claimed
US-20250152588-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2025-05-15 — — US disclosed
CN-112898210-B Process for preparing pyrimidinylcyclopentane compounds 豪夫迈·罗氏有限公司 2025-02-21 — — CN disclosed
CN-119330859-A Preparation method of (S) -3- [ tert-butoxycarbonyl (isopropyl) amino ] -2- (4-chlorophenyl) propionic acid 上海农林职业技术学院 2025-01-21 — — CN disclosed
CN-119330859-A Preparation method of (S) -3- [ tert-butoxycarbonyl (isopropyl) amino ] -2- (4-chlorophenyl) propionic acid 上海农林职业技术学院 2025-01-21 — — CN disclosed
CN-119330859-A Preparation method of (S) -3- [ tert-butoxycarbonyl (isopropyl) amino ] -2- (4-chlorophenyl) propionic acid 上海农林职业技术学院 2025-01-21 — — CN disclosed
CN-119302960-A Unit dose compositions of AKT inhibitors 南京正大天晴制药有限公司 2025-01-14 — — CN disclosed
WO-2009089352-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-07-16 — — WO disclosed
EP-2049500-A1 CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS Array Biopharma, Inc. (US) 2009-04-22 — — EP disclosed
EP-2049501-A1 HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS Array Biopharma Inc. (US) 2009-04-22 — — EP disclosed
US-20080058327-A1 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer GENENTECH, INC. 2008-03-06 — — US disclosed
US-20080051399-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. 2008-02-28 — — US disclosed
WO-2008006040-A1 HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2008-01-10 — — WO disclosed
WO-2008006032-A1 CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2008-01-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058327-A1 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer PIK3CA, DPYD, CDK2 POLB 190/4885CYP2C9 1909/4885CYP2C19 1343/4885
US-20180086722-A1 PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS DHPS, TYMP, DHFR POLB 300/4885CYP2C9 27/4885CYP2C19 14/4885
US-10435378-B2 Processes for the preparation of pyrimidinylcyclopentane compounds DHPS, TYMP, DHFR POLB 300/4885CYP2C9 27/4885CYP2C19 14/4885
US-20080051399-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, AKT1S1 POLB 613/4885CYP2C9 1373/4885CYP2C19 1175/4885
US-20160297773-A1 PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS DHPS, TYMP, DHFR POLB 283/4885CYP2C9 24/4885CYP2C19 14/4885
US-20250152588-A1 HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, AKT1S1 POLB 613/4885CYP2C9 1373/4885CYP2C19 1175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.